NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

FDA approves Bosulif for pediatric patients with CML

FDA has approved Bosulif (bosutinib) for pediatric patients ages one year and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant (R/I) to prior therapy.

September 29, 2023

Vol.49 No.36

Drugs & Targets

EU approval granted to Novartis SCEMBLIX for CML

The European Commission has approved Scemblix (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors.

September 09, 2022

Vol.48 No.32

Cancer History Project Conversation with The Cancer Letter

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

When Judy Orem learned of her chronic myeloid leukemia diagnosis in 1995, she chose interferon over a treatment that seemed more risky—a bone marrow transplant.

June 03, 2022

Vol.48 No.22

By Deborah Doroshow and Alexandria Carolan

NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

YOU MAY BE INTERESTED IN

FDA approves Bosulif for pediatric patients with CML

EU approval granted to Novartis SCEMBLIX for CML

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

Renew today!

Subscriber content

Login